The Prostate-Specific Antigen (PSA) Paradox: Navigating the Harms of Overdiagnosis, Overtreatment, and Flawed Screening.

Disclaimer: This paper is for informational and educational purposes only, based on research available as of early 2026. It does not provide medical advice or endorse the use of unapproved compounds. This information is for informational purposes only and does not replace professional medical advice. Always consult a licensed healthcare provider for concerns about your health.

The Prostate-Specific Antigen (PSA) test is frequently mischaracterized as a definitive screening tool for prostate cancer. However, the PSA test was originally developed to monitor the recurrence of disease in men already diagnosed. When used for mass screening, it routinely causes overdiagnosis and overtreatment. Because PSA is not specific to cancer, relying on this biomarker can dangerously mask aggressive tumors while falsely signaling malignancy in benign cases.

The Original Intent: Monitoring, Not Screening

The PSA test was initially approved by the U.S. Food and Drug Administration (FDA) in 1986 strictly as a tool to monitor disease progression and detect recurrence in patients who had already undergone treatment for prostate cancer. 

The test measures a protein produced by the prostate gland. However, PSA levels are a measure of prostate volume and inflammation, not a direct measure of cancer. Elevated PSA levels can be caused by numerous benign factors, including:

• Benign Prostatic Hyperplasia (BPH - normal prostate enlargement due to aging)

• Prostatitis (infection or inflammation of the prostate)

• Recent ejaculation, urinary tract infections, or vigorous exercise (e.g., cycling)

Using the PSA test for broad, asymptomatic population screening fails to differentiate between harmless, slow-growing cells and aggressive, life-threatening malignancies.

The PSA Paradox: False Negatives and False Positives

Relying on specific PSA thresholds for screening is notoriously unreliable. The biological reality of prostate cancer means that the arbitrary cutoff points commonly used in practice yield inconsistent clinical results.

Cancer With a Low PSA (False Negatives)

Many men develop aggressive prostate cancers that do not secrete proportional amounts of PSA. It is well-documented in urological studies that men can have highly aggressive, clinically significant prostate cancers with a PSA reading as low as 2 ng/mL. Relying on a low PSA alone can create a false sense of security, delaying diagnosis until the cancer has progressed.

No Cancer With a High PSA (False Positives)

Conversely, it is extremely common for men to have PSA levels over 10 ng/mL—and even into the 20s or 30s—without the presence of cancer. These dramatic elevations are often the result of large, benign prostates or chronic inflammation. When this happens, patients are subjected to invasive and uncomfortable follow-up diagnostic procedures, such as transrectal ultrasound (TRUS) biopsies, leading to unnecessary anxiety and risk of infection.

The Domino Effect: Overdiagnosis and Overtreatment

Because a single PSA value cannot distinguish between indolent (slow-growing) and aggressive cancers, mass screening creates a cascading series of medical harms.

Overdiagnosis

Overdiagnosis occurs when screening identifies a cancer that would never have caused symptoms or threatened a patient’s life during their natural lifetime. Because prostate cancer often grows incredibly slowly, many older men die with prostate cancer rather than from it. Detecting these microscopic, harmless tumors leads to the labeling of men as "cancer patients" unnecessarily, severely impacting their psychological well-being.

Overtreatment

Driven by the psychological burden of a cancer diagnosis, many men undergo aggressive, curative treatments—such as radical prostatectomy (surgical removal of the prostate) or radiation therapy—for tumors that were clinically insignificant. Overtreatment exposes men to severe, life-altering side effects without extending their life expectancy.

Common side effects of overtreatment include:

• Erectile Dysfunction (ED): Damage to the nerves surrounding the prostate during surgery or radiation can result in significant rates of impotence.

• Urinary Incontinence: Weakening of the bladder neck can result in permanent leakage or difficulty controlling urination.

• Bowel Dysfunction: Radiation therapies can cause chronic rectal inflammation, bleeding, and bowel urgency.

Current Medical Consensus: Shared Decision-Making

Because of these profound limitations, major health organizations, including the American Cancer Society and the U.S. Preventive Services Task Force, recommend against indiscriminate, mass PSA screening.

Instead, modern clinical guidelines emphasize a risk-adapted approach. This relies on shared decision-making, where a physician and patient discuss the risks and benefits of testing based on the patient's individual risk factors (e.g., family history, ethnicity, and baseline PSA trends). When screening is utilized, a rising trend in PSA over time (PSA velocity) or the ratio of free-to-total PSA is often used rather than a single static number.

For cancers that are genuinely detected and deemed low-risk, modern urology frequently utilizes active surveillance (closely monitoring the cancer with regular exams and biopsies) rather than immediate, aggressive intervention. This active management strategy successfully prevents the complications of overtreatment while ensuring that aggressive cancers are treated only if they show signs of progression.

References

1. Overdiagnosis and Overtreatment in Prostate Cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC12191725/

2. Why a one-off PSA test for prostate cancer is doing men more harm than good https://news.cancerresearchuk.org/2018/03/06/why-a-one-off-psa-test-for-prostate-cancer-is-doing-men-more-harm-than-good/

3. Prostate-Specific Antigen (PSA) Test https://www.cancer.gov/types/prostate/psa-fact-sheet

4. A Review on the Clinical Utility of PSA in Cancer Prostate https://pmc.ncbi.nlm.nih.gov/articles/PMC3392481/

5. Overdiagnosis and Overtreatment of Prostate Cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC4113338/

6. Prostate cancer screening: Should I get a prostate check? https://www.mayoclinic.org/diseases-conditions/prostate-cancer/in-depth/prostate-cancer/art-20048087

7. Prostate cancer screening: Should I get a prostate check? https://www.mayoclinic.org/diseases-conditions/prostate-cancer/in-depth/prostate-cancer/art-20048087

8. Prostate cancer: screening and early detection https://pmc.ncbi.nlm.nih.gov/articles/PMC11614164/

9. Overdiagnosis of Prostate Cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC3540879/

10. Screening for prostate cancer https://www.cancerresearchuk.org/about-cancer/prostate-cancer/getting-diagnosed/screening

11. PSA testing: When it’s useful, when it’s not https://pmc.ncbi.nlm.nih.gov/articles/PMC3183963/

12. Rethinking the Role of PSA Screening in Public Health https://ascopost.com/issues/august-15-2012/rethinking-the-role-of-psa-screening-in-public-health/

13. Prostate-Specific Antigen (PSA) Testing - Landmark Studies https://seer.cancer.gov/archive/studies/surveillance/study6.html

14. Usefulness of Total PSA Value in Prostate Disease Diagnosis https://pmc.ncbi.nlm.nih.gov/articles/PMC4949038/

15. Understanding PSA testing: A Q&A https://med.stanford.edu/news/insights/2019/11/understanding-psa-testing-a-qa.html

16. Can Prostate Cancer Be Found Early? https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/detection.html

17. Localized prostate cancer: Learn More – Low-risk prostate cancer: Active surveillance or treatment? https://www.ncbi.nlm.nih.gov/books/NBK487255/